Pharmacodynamic Effects and Predictive Biomarkers With Ruxolitinib in Operable Head and Neck Cancer
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study will identify baseline and/or pharmacodynamic biomarkers of response to
ruxolitinib, based upon association with quantitative change in tumor size following 14-21
days of neoadjuvant ruxolitinib in patients with operable HNSCC.